Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States.
Authors
Aparna Raj Parikh
Massachusetts General Hospital Cancer Center, Boston, MA
Aparna Raj Parikh , Maria Cecilia Vieira , Michelle Silver , Andrew Rava , Reina Rau , Benjamin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 63)
DOI
10.1200/JCO.2024.42.3_suppl.63
Abstract #
63
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of adherence and persistence of encorafenib in combination with cetuximab among patients with BRAF metastatic CRC in the United States (US).
First Author: Aparna Raj Parikh
Poster
2014 ASCO Quality Care Symposium
Treatment patterns of patients with metastatic colorectal cancer in a large national U.S. claims-based data.
First Author: Yue Zhong
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz